Background Generally, a short-acting beta-2 agonist (SABA) delivered via metered-dose
inhaler (MDI) is recommended for quick relief of asthma symptoms. However, in the PeRson …

Nebulizer use has been linked to worse asthma outcomes, but the precise reason (s) for this
relationship is not known. We assessed the frequency of nebulized β2-agonist use in high …

Objective: Hospitalizations for acute asthma are thought to be highly preventable through
the use of efficacious medications, though many patients have poor metered-dose inhaler …

Objective To assess the frequency of nebulizer use, describe morbidity and patterns of
medication administration, and examine the potential relationships between inhaled anti …

Background Understanding factors associated with the inappropriate or excessive use of
short-acting beta agonists (SABA) can help develop better policies. Methods We used British …

Introduction Despite little evidence for its effectiveness, many physicians believe that
delivery of medications for asthma exacerbation through nebulizer is more effective than via …

Background: Symptom control is a primary goal in asthma. We hypothesized that
administrative data regarding rescue inhaler purchases may correlate with asthma symptom …

Background Short-term studies have associated high use of short-acting β 2-agonists
(SABA) with increased risk of exacerbations, emergency visits, and asthma-related costs …

Background Short-acting β2-agonists (SABA), the most potent and rapid-acting relievers are
commonly used to provide quick relief of asthma symptoms. However, there is an increasing …

Abstract Short-acting β2-agonist (SABA) prescriptions and associated outcomes were
assessed in 1440 patients with asthma from the SABA use IN Asthma (SABINA) III study …